SynthesisThoracic cancer2024
Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data.
Synthesis in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- ZnO-Based Nanoparticles for Targeted Cancer Chemotherapy and the Role of Tumor Microenvironment: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Innovative technologies and their clinical prospects for early lung cancer screening.Clinical and experimental medicine · 2025Pooled it
- Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- [Frontiers in medicine · 2024Pooled it
- Observed and relative survival trends of lung cancer: A systematic review of population-based cancer registration data.Thoracic cancer · 2024Pooled it
- Furmonertinib inhibits non-small cell lung cancer progression throughJournal of thoracic disease · 2026Article
- Development of a Two Stage Pipeline for Robust Pulmonary Nodule Detection in Consecutive CT Slices.Biomedicines · 2026Article
- Antibody-Drug Conjugates in Lung Cancer: Promise, Progress, and Persistent Challenges.Current issues in molecular biology · 2026Review
- A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception.Cancer discovery · 2026Review
- Interventions for smoking cessation in people undergoing lung cancer screening.The Cochrane database of systematic reviews · 2026Article
- The Mediating Role of Inner Strength in the Relationship Between Illness Perception and Self-Management in Older Adults with Advanced Lung Cancer: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Folic acid-targeted albumin nanoliposomes co-loaded with paclitaxel and doxorubicin for enhanced treatment of lung cancer.Scientific reports · 2026Article
- TBX20 regulates epithelial-mesenchymal transition, maintains tumor stemness and immune factor expression, and promotes immune escape in lung cancer.Oncology letters · 2026Article
- SATB2 Mediates H3K9 Delactylation by Recruiting HDAC3 to Repress LCN2 and Inhibit Lung Tumor Growth and Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bridging Inflammation and Oncology: The Role and Therapeutic Potential of Macrophage Migration Inhibitory Factor in Lung Cancer.International journal of molecular sciences · 2026Review
- The role of senescence indicators in the linkage between high-glycemic food intake and lung cancer: a Mendelian randomization study.Journal of clinical biochemistry and nutrition · 2026Article
- Prognostic Value of Systemic Inflammation Markers (NLR and Haemoglobin) in Non-Small Cell Lung Cancer: Survival Analysis from a Real-World Single-Centre Cohort Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Determinants of quality of life among lung cancer patients: insights from a cross-sectional study.European archives of psychiatry and clinical neuroscience · 2026Article
- A Qualitative Study on the Psychological Experience of Lung Cancer Patients During the Perioperative Period.Cancer management and research · 2026Article
- Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundUsing the published survival statistics from cancer registration or population-based studies, we aimed to describe the global pattern and trend of lung cancer survival.
methodsBy searching SinoMed, PubMed, Web of Science, EMBASE, and SEER, all survival analyses from cancer registration or population-based studies of lung cancer were collected by the end of November 2022. The survival rates were extracted by sex, period, and country. The observed, relative, and net survival rates of lung cancer were applied to describe the pattern and time changes from the late 1990s to the early 21st century.
resultsAge-standardized 5-year relative/net survival rate of lung cancer was typically low, with 10%-20% for most regions. The highest age-standardized relative/net survival rate was observed in Japan (32.9%, 2010-2014), and the lowest was in India (3.7%, 2010-2014). In most countries, the five-year age-standardized relative/net survival rates of lung cancer were higher in females and younger people. The patients with adenocarcinoma had a better prognosis than other groups. In China, the highest 5-year overall relative/net survival rates were 27.90% and 31.62% in men and women in Jiangyin (2012-2013).
conclusionOver the past decades, the prognosis of lung cancer has gradually improved, but significant variations were also observed globally. Worldwide, a better prognosis of lung cancer can be observed in females and younger patients. It is essential to compare and evaluate the histological or stage-specific survival rates of lung cancer between different regions in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.